ARTICLE | Company News
Acumen, Merck Alzheimer's deal
January 13, 2004 8:00 AM UTC
Acumen Pharmaceuticals (San Francisco, Calif.) granted MRK exclusive worldwide rights to its amyloid-derived diffusible ligand (ADDL) target for use in developing monoclonal antibodies and vaccines to...